Phospho-IKKg(S43) Antibody Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9Y6K9 |
---|---|
Clone Names | 4100403 |
Gene ID | 8517 |
---|---|
Other Names | NF-kappa-B essential modulator, NEMO, FIP-3, IkB kinase-associated protein 1, IKKAP1, Inhibitor of nuclear factor kappa-B kinase subunit gamma, I-kappa-B kinase subunit gamma, IKK-gamma, IKKG, IkB kinase subunit gamma, NF-kappa-B essential modifier, IKBKG, FIP3, NEMO |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP3130a was selected from the region of human Phospho-IKKg-S43. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | IKBKG (HGNC:5961) |
---|---|
Synonyms | FIP3, NEMO |
Function | Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor (PubMed:9751060, PubMed:14695475, PubMed:20724660, PubMed:21518757). Its binding to scaffolding polyubiquitin plays a key role in IKK activation by multiple signaling receptor pathways (PubMed:16547522, PubMed:18287044, PubMed:19033441, PubMed:21606507, PubMed:27777308, PubMed:19185524, PubMed:33567255). Can recognize and bind both 'Lys-63'-linked and linear polyubiquitin upon cell stimulation, with a much higher affinity for linear polyubiquitin (PubMed:16547522, PubMed:18287044, PubMed:27777308, PubMed:19033441, PubMed:21606507, PubMed:19185524). Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Essential for viral activation of IRF3 (PubMed:19854139). Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires 'Lys- 27'-linked polyubiquitination (PubMed:20724660). |
Cellular Location | Cytoplasm. Nucleus Note=Sumoylated NEMO accumulates in the nucleus in response to genotoxic stress. |
Tissue Location | Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
IKKg is a regulatory subunit part of the IKK-signalosome complex activation. It is also considered to be a mediator for TAX activation of NF-kappa-B. Additionally, this protein could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Mutations in IKKg are the cause of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) and of familial incontinentia pigmenti type II (IP2).
References
Reiley, W., et al., Mol. Cell. Biol. 25(10):3886-3895 (2005).Wilson, G.M., et al., Mol. Biol. Cell 16(2):849-860 (2005).Nishikomori, R., et al., Blood 103(12):4565-4572 (2004).Orange, J.S., et al., J. Allergy Clin. Immunol. 114(3):650-656 (2004).Saito, K., et al., Structure (Camb.) 12(9):1719-1728 (2004).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.